AbbVie Inc. (ABBV) Revenue CAGR:9.51%(TTM)
The revenue cagr for AbbVie Inc. (ABBV) is +9.51% over the latest trailing 12-month period. Revenue CAGR uses precomputed financial statement history.
The revenue cagr for AbbVie Inc. (ABBV) stock is 9.51% over the past 12 months. The 3 year average growth rate is 3.45% and the 5 year cagr is 4.59%. Revenue CAGR measures how AbbVie Inc.'s top-line revenue has grown over time. Consistent revenue growth is a key indicator of business expansion and market share gains.
ABBV Revenue CAGR Chart
AbbVie Inc. (ABBV)
ABBV Revenue CAGR History
| Year | Start Revenue | End Revenue | Change | % Change | CAGR |
|---|---|---|---|---|---|
| 2025 | $56.33B | $61.16B | +$4.83B | +8.57% | +8.57% |
| 2024 | $54.32B | $56.33B | +$2.02B | +3.71% | +3.71% |
| 2023 | $58.05B | $54.32B | $-3.74B | -6.44% | -6.44% |
| 2022 | $56.20B | $58.05B | +$1.86B | +3.30% | +3.30% |
| 2021 | $45.80B | $56.20B | +$10.39B | +22.69% | +22.69% |
| 2020 | $33.27B | $45.80B | +$12.54B | +37.69% | +37.69% |
| 2019 | $32.75B | $33.27B | +$513.00M | +1.57% | +1.57% |
| 2018 | $28.22B | $32.75B | +$4.54B | +16.08% | +16.08% |
| 2017 | $25.64B | $28.22B | +$2.58B | +10.06% | +10.06% |
| 2016 | $22.86B | $25.64B | +$2.78B | +12.16% | +12.16% |
| 2015 | $19.96B | $22.86B | +$2.90B | +14.52% | +14.52% |
| 2014 | $18.79B | $19.96B | +$1.17B | +6.23% | +6.23% |
| 2013 | $18.38B | $18.79B | +$410.00M | +2.23% | +2.23% |
| 2012 | $17.44B | $18.38B | +$936.00M | +5.37% | +5.37% |
| 2011 | $15.64B | $17.44B | +$1.81B | +11.55% | +11.55% |
| 2010 | $14.21B | $15.64B | +$1.42B | +10.02% | +10.02% |
Quarterly Revenue — QoQ & YoY
| Quarter | Value | QoQ | YoY |
|---|---|---|---|
| Q1 2026 | $15.00B | -9.7% | +12.4% |
| Q4 2025 | $16.62B | +5.3% | +10.0% |
| Q3 2025 | $15.78B | +2.3% | +9.1% |
| Q2 2025 | $15.42B | +15.6% | +6.6% |
| Q1 2025 | $13.34B | -11.6% | +8.4% |
| Q4 2024 | $15.10B | +4.4% | +5.6% |
| Q3 2024 | $14.46B | -0.0% | +3.8% |
| Q2 2024 | $14.46B | +17.5% | +4.3% |
| Q1 2024 | $12.31B | -13.9% | +0.7% |
| Q4 2023 | $14.30B | +2.7% | -5.4% |
| Q3 2023 | $13.93B | +0.4% | -6.0% |
| Q2 2023 | $13.87B | +13.4% | -4.9% |
| Q1 2023 | $12.22B | -19.2% | -9.7% |
| Q4 2022 | $15.12B | +2.1% | +1.6% |
| Q3 2022 | $14.81B | +1.6% | +3.3% |
| Q2 2022 | $14.58B | +7.7% | +4.5% |
QoQ = change vs the prior quarter; YoY = change vs the same quarter a year earlier.
About AbbVie Inc.
AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of advanced medicines. Its extensive therapeutic portfolio encompasses several key areas: Immunology and Inflammation: Leading products include HUMIRA, an injectable therapy for autoimmune and intestinal Behçet's diseases; SKYRIZI, which addresses moderate to severe plaque psoriasis in adults; and RINVOQ, a JAK inhibitor for moderate to severe active rheumatoid arthritis in adult patients. Oncology and Hematology: For blood cancers, AbbVie provides IMBRUVICA and VENCLEXTA (a BCL-2 inhibitor), both indicated for adult patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Virology: MAVYRET offers a treatment option for individuals with chronic HCV genotype 1-6 infection. Gastroenterology and Endocrinology: The company supplies CREON, an enzyme replacement therapy for exocrine pancreatic insufficiency, and Synthroid, used to manage hypothyroidism. Linzess/Constella helps treat irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation. Women's Health and Urology: Lupron serves as a palliative treatment for conditions like advanced prostate cancer, endometriosis, central precocious puberty, and anemia caused by uterine fibroids. ORILISSA, a nonpeptide small molecule GnRH antagonist, is designed for women experiencing moderate to severe endometriosis pain. Neurology: AbbVie offers Duopa and Duodopa, a levodopa-carbidopa intestinal gel for Parkinson's disease, and Ubrelvy to treat migraines (with or without aura) in adults. The therapeutic formulation of Botox is also part of its offerings. Ophthalmology: Its eye care segment features Lumigan/Ganfort (a bimatoprost ophthalmic solution) and Alphagan/Combigan (an alpha-adrenergic receptor agonist), both aimed at reducing elevated intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension. Restasis, a calcineurin inhibitor immunosuppressant, is provided to enhance tear production, alongside other specialized eye care products. AbbVie Inc. also engages in research collaborations, including a partnership with Dragonfly Therapeutics, Inc. The company was founded in 2012 and operates from its headquarters in North Chicago, Illinois.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Robert A. Michael